Use of trimetazidine to treat diabetes patients with heart failure

Heart failure (HF) occurs commonly in modern society and is a major cause of morbidity and mortality all over the world. Cardiac energy metabolism is altered in HF and has been demonstrated to be an important factor in the development of HF in clinical and animal research. Trimetazidine is a metabolism modulator, which shifts energy production from free fatty acid to glucose oxidation. There is evidence demonstrating that trimetazidine can improve cardiac function and prognosis, even affecting cardiac electrophysiology. In this paper, recent literature on the beneficial therapeutic effects of trimetazidine on left ventricular dysfunction and HF is reviewed and discussed, especially in diabetes patients with HF.